Cytovia Therapeutics is an AI-powered discovery engine focused on the development of advanced immune therapeutics, addressing several of the most challenging unmet medical needs in cancer and immunology.
Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting.
Our R&D Center of Excellence, located in Natick, Massachusetts, is designed for pre-clinical discovery and development including NK cell biology, gene-editing, antibody and CAR development, and iNK/CAR-iNK manufacturing process development.
Cytovia’s R&D laboratories are augmented by scientific partnerships with Cellectis, CytoImmune, CytoLynx Therapeutics, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF).
Cytovia has signed an agreement to sell the global rights to its CYT-303 and CYT-338 Flex-NK Bispecific Antibodies to NAYA Biosciences.